Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas

Leukemia Research

Volumn 39, Issue 7, 2015, Pages 730-738

  Cinar, Munevver ^a   Rosenfelt, Fred ^a   Rokhsar, Sepehr ^a   Lopategui, Jean ^a   Pillai, Raju ^a   Cervania, Melissa ^a   Pao, Andy ^a   Cinar, Bekir ^a,b   Alkan, Serhan ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ABT 199; Aggressive B cell lymphomas; BCL2; Double hit and triple hit lymphomas; JQ 1; MYC

Indexed keywords

10058 F 4; 4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; ANTINEOPLASTIC AGENT; DOXORUBICIN; MYC PROTEIN; PROTEIN BCL 2; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; VENETOCLAX; VINCRISTINE; 4-(4-((2-(4-CHLOROPHENYL)-4,4-DIMETHYLCYCLOHEX-1-EN-1-YL)METHYL)PIPERAZIN-1-YL)-N-((3-NITRO-4-((TETRAHYDRO-2H-PYRAN-4-YLMETHYL)AMINO)PHENYL)SULFONYL)-2-(1H-PYRROLO(2,3-B)PYRIDIN-5-YLOXY)BENZAMIDE; FUSED HETEROCYCLIC RINGS; SULFONAMIDE;

AGED; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; B CELL LYMPHOMA CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOUBLE HIT LYMPHOMA; DRUG EXPOSURE; DRUG MECHANISM; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MONOTHERAPY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRIPLE HIT LYMPHOMA; ANTAGONISTS AND INHIBITORS; GENETICS; LYMPHOMA, B-CELL; ONCOGENE MYC;

BICYCLO COMPOUNDS, HETEROCYCLIC; GENES, MYC; HUMANS; LYMPHOMA, B-CELL; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES;

EID: 84930375647     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2015.04.003     Document Type: Article

References (40)

1. Swerdlow S.H., Campo E., Harris N.L., et al. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, IARC Press, Lyon, France. 4th ed.
2. Snuderl M., Kolman O.K., Chen Y.B., Hsu J.J., Ackerman A.M., Dal Cin P., et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol 2010, 34:327-340.
3. Campo E., Swerdlow S.H., Harris N.L., Pileri S., Stein H., Jaffe E.S. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011, 117:5019-5032.
4. Aukema S.M., Siebert R., Schuuring E., van Imhoff G.W., Kluin-Nelemans H.C., Boerma E.J., et al. Double-hit B-cell lymphomas. Blood 2011, 117:2319-2331.
5. Pillai R.K., Sathanoori M., Van Oss S.B., Swerdlow S.H. Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas. Am J Surg Pathol 2013, 37:323-332.
6. Petrich A.M., Nabhan C., Smith S.M. MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches. Cancer 2014, 120(24):3884-3895.
7. Oki Y., Noorani M., Lin P., Davis R.E., Neelapu S.S., Ma L., et al. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol 2014, 166:891-901.
8. Trabucco S.E., Gerstein R.M., Evens A.M., Bradner J.E., Shultz L.D., Greiner D.L., et al. Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma. Clin Cancer Res 2015, 21(1):113-122.
9. Sabo A., Kress T.R., Pelizzola M., de Pretis S., Gorski M.M., Tesi A., et al. Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis. Nature 2014, 511:488-492.
10. Strasser A., Harris A.W., Bath M.L., Cory S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 1990, 348:331-333.
11. Prochownik E.V., Vogt P.K. Therapeutic targeting of Myc. Genes Cancer 2010, 1:650-659.
12. Chapuy B., McKeown M.R., Lin C.Y., Monti S., Roemer M.G., Qi J., et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell 2013, 24:777-790.
13. Valent P., Zuber J. BRD4: a BET(ter) target for the treatment of AML. Cell Cycle 2014, 13:689-690.
14. Bhadury J., Nilsson L.M., Muralidharan S.V., Green L.C., Li Z., Gesner E.M., et al. BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma. Proc Natl Acad Sci USA 2014, 111:E2721-E2730.
15. Reed J.C. Double identity for proteins of the Bcl-2 family. Nature 1997, 387:773-776.
16. Schmitt C.A., Lowe S.W. Bcl-2 mediates chemoresistance in matched pairs of primary E(mu)-myc lymphomas in vivo. Blood Cells Mol Dis 2001, 27:206-216.
17. Souers A.J., Leverson J.D., Boghaert E.R., Ackler S.L., Catron N.D., Chen J., et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013, 19:202-208.
18. Vogler M., Dinsdale D., Dyer M.J., Cohen G.M. ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets. Br J Haematol 2013, 163:139-142.
19. Kiefer T., Schuler F., Knopp A., Wimmer M., Hirt C., Schaefer H.E., et al. A human Burkitt's lymphoma cell line carrying t(8;22) and t(14;18) translocations. Ann Hematol 2007, 86:821-830.
20. Cinar M., Hamedani F., Mo Z., Cinar B., Amin H.M., Alkan S. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis. Leuk Res 2013, 37:1271-1277.
21. Venkataraman G., Maududi T., Ozpuyan F., Bahar H.I., Izban K.F., Qin J.Z., et al. Induction of apoptosis and down regulation of cell cycle proteins in mantle cell lymphoma by flavopiridol treatment. Leuk Res 2006, 30:1377-1384.
22. Kang M.H., Reynolds C.P. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009, 15:1126-1132.
23. Ott G., Rosenwald A., Campo E. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. Blood 2013, 122:3884-3891.
24. Zaman S., Wang R., Gandhi V. Targeting the apoptosis pathway in hematologic malignancies. Leuk Lymphoma 2014, 55:1980-1992.
25. Khaw S.L., Merino D., Anderson M.A., Glaser S.P., Bouillet P., Roberts A.W., et al. Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. Leukemia 2014, 28:1207-1215.
26. Dos Santos Ferreira A.C., Fernandes R.A., Kwee J.K., Klumb C.E. Histone deacetylase inhibitor potentiates chemotherapy-induced apoptosis through Bim upregulation in Burkitt's lymphoma cells. J Cancer Res Clin Oncol 2012, 138:317-325.
27. Song Y.Y., Tan Y.H., Yuan Y., Guo W., Pan Z.Y., Bai O. Current perspectives in genetics of double-hit lymphoma with possible clinical implications. Cell Biochem Biophys 2014, 69:203-208.
28. Evan G.I., Littlewood T.D. The role of c-myc in cell growth. Curr Opin Genet Dev 1993, 3:44-49.
29. Dang C.V. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 1999, 19:1-11.
30. Zuber J., Shi J., Wang E., Rappaport A.R., Herrmann H., Sison E.A., et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011, 478:524-528.
31. Barrans S.L., Evans P.A., O'Connor S.J., Kendall S.J., Owen R.G., Haynes A.P., et al. The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome. Clin Cancer Res 2003, 9:2133-2139.
32. Gandhi L., Camidge D.R., Ribeiro de Oliveira M., Bonomi P., Gandara D., Khaira D., et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 2011, 29:909-916.
33. Roberts A.W., Seymour J.F., Brown J.R., Wierda W.G., Kipps T.J., Khaw S.L., et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012, 30:488-496.
34. Vandenberg C.J., Cory S. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood 2013, 121:2285-2288.
35. Ng S.Y., Davids M.S. Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma. Clin Adv Hematol Oncol 2014, 12:224-229.
36. Basso K., Dalla-Favera R. BCL6: master regulator of the germinal center reaction and key oncogene in B cell lymphomagenesis. Adv Immunol 2010, 105:193-210.
37. Baron B.W., Anastasi J., Montag A., Huo D., Baron R.M., Karrison T., et al. The human BCL6 transgene promotes the development of lymphomas in the mouse. Proc Natl Acad Sci USA 2004, 101:14198-14203.
38. Cattoretti G., Pasqualucci L., Ballon G., Tam W., Nandula S.V., Shen Q., et al. Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell 2005, 7:445-455.
39. Cerchietti L.C., Ghetu A.F., Zhu X., Da Silva G.F., Zhong S., Matthews M., et al. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell 2010, 17:400-411.
40. Johnson-Farley N., Veliz J., Bhagavathi S., Bertino J.R. ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in double hit lymphoma cells. Leuk Lymphoma 2015, 1-7.